Nutrition-optimized prehabilitation for liver cancer surgery
Nutrition-Optimized Prehabilitation's Impact on Perioperative Outcomes in Primary Hepatocellular Carcinoma: a Randomized Controlled Trial
This study tests if a special nutrition and exercise program can help people with liver cancer recover better after surgery compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06549829 on ClinicalTrials.gov |
What this trial studies
This project investigates the impact of a nutrition-optimized prehabilitation program on patients undergoing surgery for primary hepatocellular carcinoma. Patients are randomized into an experimental group receiving tailored nutritional and exercise interventions and a control group receiving standard prehabilitation. The interventions are conducted for two weeks prior to surgery, with follow-up assessments to monitor postoperative recovery and complications. Clinical blood tests are performed at various stages to evaluate the patients' health status.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 diagnosed with primary liver cancer who are eligible for surgical treatment.
Not a fit: Patients with liver metastases, severe malnutrition that cannot be corrected by oral nutrition, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance recovery and reduce complications for liver cancer patients undergoing surgery.
How similar studies have performed: While similar nutritional optimization approaches have shown promise in other surgical contexts, this specific application in liver cancer surgery is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patients diagnosed with primary liver cancer.
* Patients between the ages of 18 and 70.
* Patients who are feasible for surgical treatment after clinical evaluation. ④Major organ function meets the following conditions: neutrophil count \>1.5\*109/L; platelet count \>100\* 109/L; hemoglobin \>90g/L; transaminase and creatinine \<twice the upper limit.
Exclusion Criteria:
* Patients with liver metastases or combined with other tumors. ②Patients with allergy to the ingredients of nutritional preparations.
* Patients with severe malnutrition who cannot eat by mouth. ④Patients with hyperthyroidism, fistula, and combined digestive system diseases.
Where this trial is running
Hangzhou, Zhejiang
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Yuan Ding
- Email: dingyuan@zju.edu.cn
- Phone: +86 18858101960
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.